From single excipients to dual excipient platforms in dry powder inhaler products

Jagdeep Shur, Robert Price, David Lewis, Paul M. Young, Grahame Woollam, Dilraj Singh, Stephen Edge

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)
31 Downloads (Pure)


Recent years have seen a marked diversification of excipient based formulation strategies used for the development and commercialisation of dry powder inhaler (DPI) products. These innovative approaches not only provide benefits to patients and health care professionals through the availability of a wider range of therapeutic DPI products, but, importantly, also allow formulators to exploit the potential opportunities that excipients provide for the development of DPIs. Whilst many DPI products have, and continue to be developed using a single formulation excipient, the commercialisation of DPI products which contain the two excipients lactose monohydrate and magnesium stearate, namely the ‘dual excipient platform’ has recently been achieved. This article provides an overview of the background and current status of the development of such ‘dual excipient platform’ based DPI products.
Original languageEnglish
Pages (from-to)374-383
Number of pages10
JournalInternational Journal of Pharmaceutics
Issue number2
Publication statusPublished - 2016
Externally publishedYes

Bibliographical note

Crown Copyright 2016. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.


  • Dry powder inhaler
  • Excipients
  • Formulation
  • Inhalation


Dive into the research topics of 'From single excipients to dual excipient platforms in dry powder inhaler products'. Together they form a unique fingerprint.

Cite this